Psychedelic Stock Gainers And Losers From January 1, 2024
Portfolio Pulse from Benzinga Insights
The article reports on the performance of psychedelic stocks from January 1, 2024. Cybin (CYBN) saw a gain, while ATAI Life Sciences (ATAI), Mind Medicine (MNMD), Compass Pathways (CMPS), and GH Research (GHRS) experienced losses.
January 01, 2024 | 9:30 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
ATAI Life Sciences shares dropped by 5.37%, closing at $1.41.
The significant drop in ATAI's stock price could indicate negative sentiment or disappointing developments, likely leading to bearish short-term investor behavior.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 80
NEGATIVE IMPACT
Compass Pathways shares fell by 2.98%, closing at $8.80.
The drop in Compass Pathways' stock price could be due to market volatility or negative news, suggesting a cautious short-term outlook for investors.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 80
NEGATIVE IMPACT
GH Research shares declined by 1.62%, closing at $5.45.
GH Research's stock price drop suggests investor caution, which may continue to affect the stock's performance in the short term.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 80
NEGATIVE IMPACT
Mind Medicine shares decreased by 5.26%, closing at $3.60.
Mind Medicine's decline may reflect broader market trends or company-specific issues, potentially leading to a negative short-term outlook.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 80
POSITIVE IMPACT
Cybin shares increased by 1.49%, closing at $0.41.
Cybin's stock price increase is a positive sign and may attract investor interest in the short term, potentially leading to further gains.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 80